Skip to main content
OpenTrials
Completed

NCT Number: NCT05383508

Nicotine Pharmacokinetics Following Use of the P4M3 Gen 2.0 E-Cigarette Compared to Smoking Cigarettes

This is a single-center, randomized, controlled, open-label, cross-over study with healthy adult smokers. The study will investigate the nicotine pharmacokinetic (PK) profiles of two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette, compared to smoking combustible cigarettes.

In addition, pharmacodynamic (PD) effects (subjective effects and related behavioral assessments), will be evaluated to provide further insights on product evaluation, craving, liking, puffing topography. The study will be conducted with three periods and six sequences in a cross-over design.

This study is exploratory and there is no pre-specified hypothesis to be tested.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Nicotine Vaping Behavior Nicotine Smoking Vaping

Age range

24 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

High Point Clinical Trials Center (HPCTC)

High Point, North Carolina, 27265, United States

About this study

The purpose of the study is to evaluate the nicotine pharmacokinetics (PK) profiles of two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette versus cigarettes following a six minutes ad libitum use period. In addition, pharmacodynamic effects (PD), including subjective effects and related behavioral assessments, as well as human puffing topography (HPT) will be evaluated, to provide further insights on P4M3 Gen 2.0 product acceptance and product use. Safety will be assessed throughout the study.

The aim is to evaluate if P4M3 Gen 2.0 can provide an acceptable alternative to smoking cigarettes in terms of both, nicotine delivery and sensorial satisfaction for current adult smokers who would otherwise continue smoking cigarettes.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject has signed the ICF and is able to understand the information provided in the ICF.
  • Subject has smoked continuously for at least the last 3 years prior to the Screening visit.
  • Subject has smoked ≥ 10 commercially available cigarettes per day for 4 weeks prior to Screening Visit and Admission.
  • Subject does not plan to quit smoking cigarettes or using other nicotine or tobacco containing products in the next 3 months.
  • Smoking, healthy subject as judged by the Investigator or designee based on available assessments from the Screening period.

Exclusion criteria

  • As per the Investigator's judgment, the subject cannot participate in the study for any reason other than medical.
  • Subject has donated or received whole blood or blood products within 30 days prior to Screening Visit.
  • BMI < 18.5 kg/m2 or > 35.0 kg/m2.
  • Subject has received medication within 14 days or within 5 half-lives of the drug prior to Admission (whichever is longer), which has an impact on CYP2A6 activity.
  • Subject has a positive serology test for HIV 1/2, Hepatitis B or Hepatitis C.
  • Subject has a history of alcohol abuse that could interfere with the subject's participation in study.
  • Subject has a positive urine drug test.
  • Subject has a positive alcohol breath test.
  • Subject has participated in another clinical study within 30 days prior to the Screening Visit.
  • Subject is pregnant (does not have negative pregnancy tests at Screening Visit and at Admission) or is breastfeeding.
  • For women of childbearing potential only: subject does not agree to use an acceptable method of effective contraception.

Treatment and study plan

CA35

Other

Nicotine concentration: 3.5 % e-liquid flavor: Tobacco

Other names: P4M3 variant CA35

CM35

Other

Nicotine concentration: 3.5 % e-liquid flavor: Menthol

Other names: P4M3 variant CM35

CIG

Other

Subjects' preferred brand of commercially available, regular or mentholated cigarettes

Primary outcomes

  1. Background-corrected Maximum Plasma Concentration [Cmax]

    Time frame: T0 = start of product use. From day 1 to day 3, blood was drawn 5 minutes prior to T0 (day 1 only), and then 1, 2, 4, 6, 8, 10, 12, 15, 30 minutes, 1, 2, 4, 10 and 24 hours after T0. (Note that sample taken 24 hours after T0 on day 1 and day 2 only.)

    To measure Cmax from 6 minutes ad libitum use for two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette and for subjects smoking cigarettes.

  2. Background-corrected Time to the Maximum Concentration [Tmax]

    Time frame: T0 = start of product use. From day 1 to day 3, blood was drawn 5 minutes prior to T0 (day 1 only), and then 1, 2, 4, 6, 8, 10, 12, 15, 30 minutes, 1, 2, 4, 10 and 24 hours after T0. (Note that sample taken 24 hours after T0 on day 1 and day 2 only.)

    To measure Tmax from 6 minutes ad libitum use for two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette and for subjects smoking cigarettes.

  3. Area Under the Background-corrected Concentration-time Curve From Start of Product Use to Time of Last Quantifiable Concentration and Extrapolated to Infinity.

    Time frame: T0 = start of product use. From day 1 to day 3, blood was drawn 5 minutes prior to T0 (day 1 only), and then 1, 2, 4, 6, 8, 10, 12, 15, 30 minutes, 1, 2, 4, 10 and 24 hours after T0. (Note that sample taken 24 hours after T0 on day 1 and day 2 only.)

    To measure the area under the background-corrected concentration-time curve (AUC) from start of product use from 6 minutes ad libitum use for two e-liquid variants used with the P4M3 Gen 2.0 e-cigarette and for subjects smoking cigarettes.

  4. Maximum Ratio of Background-corrected Concentration Over Time

    Time frame: T0 = start of product use. From day 1 to day 3, blood was drawn 5 minutes prior to T0 (day 1 only), and then 1, 2, 4, 6, 8, 10, 12, 15, 30 minutes, 1, 2, 4, 10 and 24 hours after T0. (Note that sample taken 24 hours after T0 on day 1 and day 2 only.)

    To measure the maximum ratio of background-corrected concentration over time, from T0 (excluded) to Tmax (included)

Sponsors and collaborators

Lead sponsor

Philip Morris Products S.A.

Industry

Registry information

Official study title

A Single-center, Randomized, Controlled, Open-label, Cross-over Study in Healthy Subjects to Investigate the Nicotine Pharmacokinetic Profiles of 2 Variants of P4M3 Gen 2.0, an Electronic Nicotine Delivery System, Compared to Cigarettes

Important dates

Study start
2022
Primary completion
2022
Study completion
2022
First posted
May 20, 2022
Registry last updated
Apr 26, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.